Alterity Therapeutics (ADR) (ATHE)
Develops ATH434, a clinical candidate for multiple system atrophy and related Parkinsonian disorders.
$3.78
vs last close+0.00 (+0.03%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 2.18% | 394.5K ADS | |
|---|---|---|---|
| 22 holders · as of Jun 30, 2026 | |||
| Insiders | 8.53% | 1.55M ADS | |
| 4 holders · as of Sep 8, 2026 | |||
| Other | 89.29% | 16.19M ADS | |
| remainder | |||
18.13M ADS (1 ADS = 12 ordinary shares) as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
22 holders · 394.5K shares · 7 new positions · 14 increased · 0 reduced · 0 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Twin Lakes Capital Management, LLC | 139.3K | 0.77% | 0 | Aug 18, 2026 |
| Morgan Stanley | 63.1K | 0.35% | +4.7K | Aug 13, 2026 |
| Greenleaf Trust | 62.0K | 0.34% | +30.0K | Jul 21, 2026 |
| HB Wealth Management, LLC | 58.5K | 0.32% | 0 | Jul 29, 2026 |
| Citadel Advisors LLC | 37.6K | 0.21% | +17.5K | Sep 2, 2026 |
| HRT Financial LP | 17.3K | 0.10% | +17.3Knew | Aug 14, 2026 |
| BNP Paribas Arbitrage, SNC | 10.2K | 0.06% | +3.4K | Aug 13, 2026 |
| Gamma Investing LLC | 2.3K | 0.01% | +453 | Jul 7, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 31, 2026 | Peter Ashley Marksdirector | Purchase · 2 lots | 95,240 | $0.5000 | 191,340 |
| Aug 31, 2026 | David Allen Stamlerdirector, officer: Chief Executive Officer | Purchase | 47,620 | $0.5000 | 0 |
House and Senate disclosures
Not reported.